EODData

MEMBERSHIP REGISTER LOG IN

FRA, 36X: ASCENTAGE PHARM. DL-0001

17 Aug 2026
LAST:

3.560

CHANGE:
 0.08		OPEN:
3.840		HIGH:
3.840		ASK:
0.000		VOLUME:
0
CHG(%):
2.20		PREV:
3.640		LOW:
3.560		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
17 Aug 263.8403.8403.5603.5600
14 Aug 263.9403.9403.6403.6400
13 Aug 264.1004.1003.8003.8000
12 Aug 263.9603.9803.7203.7200
07 Aug 263.9803.9803.7203.7200
06 Aug 263.6403.6603.4203.4200
05 Aug 263.6803.6803.2203.2200
04 Aug 263.5803.5803.3403.3400
03 Aug 263.6003.6003.3403.3400
31 Jul 263.7403.7403.7203.7200

PROFILE

Name:ASCENTAGE PHARM. DL-0001
About:Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Sector:Healthcare
Industry:Biotechnology
Address:Suzhou Industrial Park, Suzhou, China, 215000
Website:https://www.ascentage.cn
ISIN:KYG0519B1023

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-1.07 
Price to Sales:2.61 
Price to Book:8.74 
Profit Margin:-2.16 
Operating Margin:-1.93 
Return on Assets:-0.23 
Return on Equity:-1.55 
Revenue:74.21M 
Shares:371.85M 
Market Cap:1.324B 

TECHNICAL INDICATORS

MA5:3.693.6%
MA10:3.550.3%
MA20:3.632.0%
MA50:3.662.7%
MA100:4.2118.4%
MA200:5.1745.3%
STO9:38.64
STO14:38.64
RSI14:43.33
WPR14:-41.38
MTM14:-0.16
ROC14:-0.04 
ATR:0.33 
Week High:4.1015.2%
Week Low:3.560.0%
Month High:4.1616.9%
Month Low:3.2245.3%
Year High:10.00180.9%
Year Low:0.85321.3%
Volatility:27.68